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TRENDS IN PREVALENCE OF OBESITY AND MEDICAL COSTS IN 
ASTHMA PATIENTS IN THE UNITED STATES
Choi IS1, Noyes D1, Kwon JW1, Sohn HS2, Suh K1, Yang JH1
1Rutgers University, Piscataway, NJ, USA, 2Sook Myung Women’s University, Seoul, South
Korea
OBJECTIVES: To investigate trends in the prevalence of obesity and annual medical 
costs in normal and obese patients with asthma from 2001–2006. METHODS: This
cross-sectional analysis utilized data from the 2001–2006 Medical Expenditure Panel
Surveys. Self report of a diagnosis of asthma or ICD-9-CM code: 493, with exclusion
of patients with pregnancy, malignancy, kidney dialysis, immunodeﬁ ciency, age 18 
or q75 years old, or body-mass-index(BMI) of 18.5, identiﬁ ed 10,402 asthma 
patients. Patients with BMI’s of q30 and 18.5 to 25 were classiﬁ ed as obese and 
normal, respectively. Medical costs included all treatment costs, except dental or injury
costs, with costs related to the respiratory system being those associated with ICD-9
codes 460–516. Bootstrap method was used to calculate the standard error (SE) of 
medical costs, while t-test was used to compare medical costs. All costs were converted
to 2006 U.S. dollars. Data were analyzed using SAS and STATA. RESULTS: Age 
adjusted prevalence of obesity was 25.9% and 26.4% among the total population, 
but 35.1% and 35.6% among asthma patients in 2001 and 2006, respectively. While
average medical costs in asthma patients with normal BMI maintained a steady level 
from $2911 (SE:$492) in 2001 to $2630 (SE:$286) in 2006, those costs increased by 
30% from $4442 (SE:$371) in 2001 to $ 5776 (SE:$401) in 2006 (P  0.0101) in 
obese asthma patients. Costs related to the respiratory system in obese asthma patients
did not change over time, with increases in medication costs but decreases in inpatient 
costs. CONCLUSIONS: Even though the prevalence of obesity remained consistent 
from 2001 to 2006, the average medical cost in asthma patients with obesity increased 
signiﬁ cantly, suggesting an upward trend in the economic burden of obesity. Effective 
strategies to prevent or reduce obesity should be introduced as a cost-effective inter-
vention in asthma patients.
RESPIRATORY-RELATED DISORDERS – Patient-Reported 
Outcomes Studies
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CAN OLDER, CHRONICALLY ILL ADULTS USE ELECTRONIC DIARIES?
COMPLIANCE RATES IN A PROSPECTIVE STUDY OF PATIENTS
WITH COPD
Cates C, Roberts L, Eremenco S, Wilcox TK, Leidy NK
United BioSource Corporation, Bethesda, MD, USA
OBJECTIVES: Electronic data capture for daily diary and survey-style patient-
reported outcomes (e-PRO) is becoming widespread. Concern has been expressed that
older adults may have difﬁ culty with this methodology, particularly e-diaries requiring
independent completion and data transmission at home. Objective: To evaluate e-diary
compliance rates in adults with stable and acute chronic obstructive pulmonary disease 
(COPD) using data from the EXACT (Exacerbations of Chronic Pulmonary Disease
Tool) prospective item-reduction and validation study. METHODS: N  410; 188
stable patients were asked to complete an e-diary for 7 days; 222 acute patients were 
to complete the e-diary for 28 days and again on days 60–67. Site coordinators pro-
vided standardized training, take-home instructions, and a toll-free helpdesk number. 
Patients were instructed to complete the 30-item diary each evening during a 6-hour
variable window (based on bedtime) and upload data daily. Audible alarms were
used as reminders. Compliance feedback (%) was provided via PDA each entry day. 
Site coordinators tracked compliance via web portal, contacting patients after two 
missed entries. Centralized compliance monitoring was performed to detect low rates
and re-train sites. RESULTS: Mean age  65 years (o 10); 48% male; 77% retired 
or disabled; 64% a high school education; mean FEV-1% predicted  51% (o 20);
92% moderate to severe disease; 75% of acute patients had moderate to severe
exacerbations based on clinician rating. Study retention was 99% and 88% for the
stable and acute groups, respectively; compliance rates were 96% for days 1–7 in 
stable patients and 94% for days 1–28 in acute patients. CONCLUSIONS: High 
compliance rates were observed in stable and acute patients with COPD participating
in a study that included patient training, real-time reminders, and daily monitoring. 
Further study of compliance over longer periods of time and an evaluation of the most
effective compliance enhancement methods within and across patient populations is 
warranted.
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Spain CV, McHorney CA
Merck & Co., Inc., West Point, PA, USA
OBJECTIVES: We identify commonly-reported reasons that patients with chronic 
disease either do not ﬁ ll a new medication prescription (non-fulﬁ llment) and/or
elect to stop taking a medication without their physician telling them to do so (non-
persistence). METHODS: Participants were sampled from a nationally-representative,
internet-based panel of US adults with chronic diseases. 29,018 eligible respondents 
answered questions about medication fulﬁ llment or persistence and their medication-
related beliefs. We collected reasons for non-fulﬁ llment or non-persistence. Statistical
analyses were conducted to assess the association between reported reasons and
chronic disease, demographics, or beliefs. RESULTS: Among the 11,301 respondents
who had received at least one new prescription in the previous year, 3.8% reported 
never ﬁ lling the prescription. Non-fulﬁ llment rates ranged from 1.9% for diabetes 
to 11.0% for osteoporosis. Among the 28,973 respondents currently prescribed 
medication(s), 13.7% reported non-persistence for at least one prescription in the 
previous year. Non-persistence was highest for medications for osteoporosis (19.1%),
and lowest for respondents with hypertension medications (5.6%). Three reasons 
were the most commonly reported for non-fulﬁ llment and non-persistence: cost-
related barriers (51% and 42%, respectively), medication concerns (47% and 50%), 
and low perceived need for medications (30% and 31%). The frequency of the reasons 
for non-persistence varied substantially by chronic disease (all P a 0.02). CONCLU-
SIONS: Future efforts to improve medication adherence should address patients’
medication concerns, perceived need for medications, and perceived medication 
affordability. The results of our study can inform the design and evaluation of adher-
ence interventions.
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ASSOCIATION BETWEEN COMPLIANCE AND RESPIRATORY-RELATED
COSTS FOR PATIENTS WITH COPD TREATED WITH MAINTENANCE
THERAPY
Halpern R1, Curtice TG2, Marfatia A3, Woodruff KB3, Shah H2
1i3 Innovus, an Ingenix Company, Eden Prairie, MN, USA, 2Boehringer Ingelheim 
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OBJECTIVES: Compare respiratory-related costs between cohorts of compliant and 
non-compliant patients with chronic obstructive pulmonary disease (COPD) initiated 
on maintenance therapy (tiotropium or ﬂ uticasone/salmeterol). METHODS: This ret-
rospective cohort analysis used medical and pharmacy claims from a large national
U.S. health plan. Patients were commercial health plan enrollees q40 years old with q1 
tiotropium or ﬂ uticasone/salmeterol ﬁ ll between December 1, 2004 and December 31,
2005, COPD, and q12 (up to 18) months continuous enrollment. Patients had no ﬁ lls 
of tiotropium, ﬂ uticasone/salmeterol, salmeterol, or formoterol during a six-month 
pre-index period. Cohorts were “compliant” (medication possession ratio [MPR] q
80%) or non-compliant” (MPR  80%). Respiratory-related inpatient costs, medical
costs, and total (medical  outpatient pharmacy) costs were modeled with generalized
linear model (GLM) with log link and gamma distribution. Costs were adjusted to 
2006 dollars. Covariates included cohort, demographics, and COPD severity, index 
pharmacy claim from pulmonologist (intensity of services), and comorbi dities.
RESULTS: The sample included 558 (12.3%) compliant and 3979 (87.7%) non-com-
pliant subjects (total N  4537). Compliance compared with non-compliance was
associated with: higher total respiratory-related costs (cost ratio  1.47, 95% conﬁ -
dence interval [CI]  1.13–1.90, p  0.01); lower respiratory-related medical costs (cost
ratio  0.64, CI  0.44–0.92, p  0.05); and lower respiratory-related inpatient costs
(cost ratio  0.49, CI  0.32–0.75, p  0.01). COPD severity, baseline oxygen use, and 
pulmonologist index claim were signiﬁ cantly associated with higher respiratory-related
total costs and medical costs. When treatment (tiotropium vs. ﬂ uticasone/salmeterol)
was added as a covariate, compliance remained signiﬁ cant and treatment was not. 
CONCLUSIONS: Compliance was associated with higher total respiratory-related 
costs, because sustained therapy was correlated with higher respiratory-
related outpatient pharmacy costs, and likely also with higher respiratory-related 
medical services consumption. However, compliance was also associated with lower 
respiratory-related medical and inpatient costs. Costs were not linked directly with
clinical outcomes, but outcomes may be indirectly inferred from medical and inpatient
costs. Further research should examine compliance with respect to outcomes and
costs.
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ADJUSTING THE NICOTINE DOSE: THE KEY TO A SUCCESSFUL, 
“TAILORED” METHOD OF QUITTING SMOKING
Taieb C
Pierre Fabre, Boulogne, France
In a recent report, AFSSAPS (the French Health Products Safety Agency) discussed to
what extent the dose selected constitutes an important success factor. OBJECTIVES:
Assess the impact of quitting smoking in subjects receiving treatment by nicotine 
patches, combined in some cases (and others not, depending on the practitioners’ 
approach) with nicotine pastilles to suck. METHODS: Each of the subjects was
included after they had expressed, during the spontaneous consultation, their desire 
to quit smoking. The cohort being pragmatic, no prescription advice was given,
directly or indirectly, to the investigating doctors. The doctors were recruited by an
independent service provider. RESULTS: A total of 215 subjects were recruited by 67
general practitioners. Two analysis groups were organised, the ﬁ rst group being treated 
with a transdermal device or skin patch (n  93) and the second with a transdermal 
device combined with pastilles (n  122). After 6 months, the rate of abstinence in the 
“Patch  Pastille” group was 62.1% versus 39.7% in the “Patch only” group, the 
difference observed being signiﬁ cant (p  0.008). CONCLUSIONS: This cohort, 
carried out in real conditions, highlights – in subjects wishing to quit smoking – the
relevance of adjusting the dose with the help of pastilles. Therefore, it would appear 
that, for subjects quitting smoking, combining pastilles with a transdermal nicotine 
substitute is indispensable. The role of the health professional initiating the quitting 
programme is therefore of prime importance.
